Dr Gelareh Eslamian

Consultant Medical Oncologist


Specialises in

I acquired my medical degree from Babol University in Iran; continued my foundation years and medical training in the Peninsula deanery, Devon and completed my medical oncology training in Wessex, South Yorkshire (Weston Park Hospital), London (Guys and St Thomas' and St George's hospitals) and Kent deaneries.

I specialise in treatment of breast, oesophagus, gastric and pancreato-biliary cancers with a main focus and passion on treating breast cancer. I would encourage active participation in clinical trials and aim to provide the latest available cancer treatment to my patients. I have extensive experience in systemic anti-cancer therapies including chemotherapy, immunotherapy, monoclonal antibodies and endocrine treatments.

I am a core member of the Windsor Breast Multi-Disciplinary Team and the Royal Berkshire UGI MDT. I have extensive experience in treating acutely unwell cancer patients and have a dedicated weekly ward (Acute Oncology). I am the chemotherapy lead for Berkshire Cancer Centre and Chair of the Chemotherapy Steering Group.

I am also interested in medical education and am a clinical supervisor for medical trainees.


Treatment information

Some of the principal treatments carried out by Dr Gelareh Eslamian at Spire include:


Other treatments

  • Immunotherapy
  • Targeted and endocrine treatments

Get in touch

Important information about COVID-19 tests

COVID-19 testing or antibody tests are not available as a standalone service at Spire Dunedin Hospital.


Marketing Information

Spire would like to provide you with marketing information about products and services offered by Spire and by selected third-party partners. If you do not consent for us to process your personal data for marketing activities, we will still be able to contact you about your enquiry.

We may contact you by email, SMS or phone about your enquiry. If we try to contact you by phone (mobile and/or landline) and you are not available, we may leave you a voicemail message. We may also use your details to contact you about patient surveys we use for improving our service or monitoring outcomes, which are not a form of marketing.

Submit my enquiry

Additional information

  • I have been a co-investigator in numerous oncology phase 3 clinical trials and the following breast cancer trials ARTemis, EMILIA, AZURE, D-CARE, MANTA, OLYMPIA, PERESHONE, ROSCO and PALOMA-2.
  • Dissertation for final year of MD, a research project with “Effects of soy protein on serum hyperlipidaemia”.  It was a non-randomised clinical trial study on 98 patients; they were divided in two groups: case (diet+soy) and control (diet).  I scored distinction on this research project.


PEAR Study “243P UK experience of management of pregnancy associated breast cancer”: A national retrospective review of UK practice. ANNALS of ONCOLOGY
September 2020

Poster presentation of PEAR Study “UK experience of the management of Pregnancy -associated Breast cancer: A national retrospective review of UK practice. ESMO 2020, 243P.

Immune checkpoint inhibitor induced large vessel vasculitis, A case report of immune related toxicity post Ipilimumab and Nivolumab, BMJ, Volume 13
May 2020

Poster presentation of “The assessment of Bone Mineral Density (BMD) and fracture risk after three years of adjuvant zoledronic acid in post-menopausal ER+ early breast cancer”. UKBCG.
November 2019

Poster presentation” UK practice in management of pregnancy associated breast cancer”. UKBCG
November 2018

Review article of Eribulin as a novel microtubule targeting agents and its use in breast cancer. “Efficacy of Eribulin in breast cancer, a short report on new emerging data” in OncoTargets and Therapy in February 2017. G. Eslamian, R. Young, C. Wilson.

Poster Presentation “Pertuzumb as part of triple therapy in metastatic HER-2 positive breast cancer”. London UKBCG
November 2017

I have accepted educational sponsorship to attend international oncology meetings. I have no financial interest in any pharmaceutical company.
Private secretary Donna Gardner
Private secretary telephone 0118 955 3531
Private secretary email Donna.gardner@spirehealthcare.com